Search PubMed⌕ Search

Biomedical subjects

B Beake

Publications and source records attributed to B Beake.

5 recordsLinked to original sources

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.

Sibutramine is a serotonin and norepinephrine reuptake inhibitor that has shown efficacy as a weight loss and weight maintenance agent. Because of the abuse liability and physical dependence potential of amphetamines and related antiobesity agents, this study evaluated the abuse potential of sibutramine and compared it with that of dextroamphetamine and placebo in recreational stimulant users. Thirty-one male recreational stimulant users participated in this single-site, Latin square crossover study that compared the effects of two doses of sibutramine (20 mg and 30 mg) to dextroamphetamine (20 mg and 30 mg) and placebo, using a series of validated subjective scales or questionnaires. For scales measuring stimulation and euphoria, there was a greater mean response for dextroamphetamine 30 mg versus 20 mg, with both doses having a significantly greater stimulant and euphoric effect than placebo at the majority of time points (p < 0.05); responses for both doses of sibutramine were statistically indistinguishable from placebo at all time points. Responses to "street value" and "most enjoyed study session" questions confirmed that sibutramine lacks abuse potential; mean cash value estimates of street value were significantly greater for both dextroamphetamine doses than for placebo or either sibutramine doses (p < 0.05), and the rank order of session enjoyment placed both doses of sibutramine last. Together with the relatively late Tmax of the active metabolites (3-4 hours), this short-term, single-dose study provides strong evidence that sibutramine does not have the potential for abuse that is characteristic of amphetamines and that it is indistinguishable from placebo in abuse potential.

Adult↗

Methaqualone.

Methaqualone is considered a sedative hypnotic drug with a pattern of pharmacological effects similar to those of barbiturates such as pentobarbital. It does have chemical similarities to the barbiturates but was, in fact, synthesized as part of an Indian program looking for antimalarial drugs (Brown and Goenechea, 1973). Methaqualone was selected for the focus of this study five years ago, because of its popularity as a euphoriant among casual recreational drug users in the Boston area. Methaqualone, instead of a barbiturate hypnotic, was therefore used to test our proposed methodology for the assessment of the abuse liability of sedative drugs. As one reviews the history of the clinical use and illicit abuse of methaqualone, it appears particularly unfortunate that a study of this sort was neither completed nor available to our Food and Drug Administration (FDA) and Drug Enforcement Agency (DEA) in 1965. It was at this time that the drug was approved for prescription use and placed in Schedule V, a schedule which essentially places no restrictions on the clinical use of a prescription drug (Falco, 1976). This paper will both review the development of methaqualone and present an experimental methodology for assessing its abuse liability under seminaturalistic conditions.

Adult↗

Comparative study of the abuse liability of alprazolam, lorazepam, diazepam, methaqualone, and placebo.

Subjective effects of two benzodiazepines--alprazolam and lorazepam--were compared with two drugs of known abuse potential--diazepam and methaqualone--and placebo. This double-blind, crossover trial tested 30 casual recreational sedative users in a seminaturalistic setting. Methaqualone was more euphoriant and less sedative than the benzodiazepines. Diazepam and lorazepam were more euphoriant than placebo; alprazolam's euphoriant effect did not differ from these treatments. On other measures of abuse liability the benzodiazepines rated similarly, diazepam rating highest.

Adolescent↗

Assessment of the abuse liability of buspirone in recreational sedative users.

The abuse potential of buspirone, a new dopaminergic antianxiety drug, was evaluated by assessing its subjective effects in standard (10 mg) and high (40 mg) doses. These were compared with methaqualone (300 mg), diazepam (20 mg and 10 mg), and placebo in 24 casual recreational sedative users. Addiction Research Center Inventory scales measuring euphoria, sedation, dysphoria, and abuse liability were used as dependent measures. Groups of subjects received all treatments in randomized order in six weekly 4-hour sessions. Compared to placebo, methaqualone caused elevated scores on euphoria, physical sedation, and abuse liability scales compared to placebo, while 40 mg buspirone caused increased physical sedation, increased physical and mental dysphoria, and lower abuse liability scores. Overall, buspirone at 40 mg appeared unlikely to be reinforcing to recreational illicit drug users; the 10 mg dose was not discriminable from placebo or 10 mg diazepam. Diazepam at 20 mg showed some euphoriant effect compared to placebo.

Anti-Anxiety Agents↗